MR studies of the protective factors of BPH SGK1, EGF and ENPP1 in GSE7307 and GSE132714 showed a consistent trend of expression significantly downregulated in the disease group, which could be used as biomarkers for Shenhailong formula treating BPH. The gene discussed is EGF; the disease is benign prostatic hyperplasia.